Milestone Pharmaceuticals(MIST) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or ef icacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ...